Agents that downregulate the induction of monocyte/macrophage tissue factor (TF) activity may attenuate the thrombotic risk associated with mechanical restoration of vessel patency or artificial arterial grafting. In such events, procoagulant macrophages in the atherosclerotic plaque and procoagulant monocytes adherent t o artificial materials may be exposed to the blood stream. lshii et al (BIood80:2556,1992) reported that induction of endothelial TF is downregulated by all-trans retinoic acid (ATRA), and Conese et al (Thromb Haemost66662.1991) reported that retinoids downregulate monocyte procoagulant activity (PCA). These findings led us t o investigate the effect of ATRA on monocyte TF expression, and t o study the effect of ATRA on monocyte-induced thrombus formation in a model system of human arterial thrombogenesis. Induction of PCA in human peripheral blood monocytes by 0.5 pg/mL lipopolysaccharide (LPS) was dose dependently reduced by ATRA, reaching a reduction of 56% at mol/L ATRA ( P < .0001). A 389'0 reduction ( P < .0007) in LPS-induced TF antigen expression was observed at an ATRA concentration of lo-' mol/L. Adherence of monocytes t o plastic cover slips (Thermanox, Miles Lab-CTIVATION OF THE extrinsic pathway of coagulation by monocyte/macrophage tissue factor (TF) is considered an important contributor to thromboembolic disorders.
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Macrophages expressing TF are abundant in atherosclerotic plaques,"' and may become exposed to the blood stream after plaque rupture. In addition, expression of TF by blood monocytes is apparently induced by their adhesion to artificial s~r f a c e s ,~-~ such as arterial graft materials.
The latter process presumably plays a role in artificial graft failure.
We have recently ahown that adherent monocytes expressing TF-procoagulant activity efficiently elicit fibrin deposition and platelet thrombus formation, when exposed to nonanticoagulated human blood at arterial blood flow conditions4 in a parallel-plate perfusion chamber device."' It was apparent that thrombus formation was TFFVlla-dependent because a monoclonal antibody (MoAb) blocking TFFVIIa-induced coagulation inhibited the thrombotic events at the cell surface. These experiments indicate that monocyte TF expression is of importance in clinical situations when cellular TF is presented to the blood stream.
Recently it was shown by Ishii et al'" that induction of TF in vascular endothelial cells by tumor necrosis factor can be downregulated by all-truns retinoic acid (ATRA). Retinoids have also been shown to reduce monocyte procoagulant activity.' ' Other beneficial antithrombotic effects as-oratories, Naperville, IL) also triggered induction of cellular PCA, which was inhibited by more than 80% by an anti-TF monoclonal antibody (MoAb) ( P c .002). Inclusion of ATRA (IO-' mol/L) reduced this PCA by 4096 ( P < .03), and the TF antigen expression by 3090 ( P < .0001). Exposure of Thermanox adherent monocytes t o flowing nonanticoagulated human blood in a parallel-plate perfusion chamber device at an arterial wall shear rate of 650 s" elicited significant fibrin deposition and platelet thrombus formation. Partial interruption of this thrombus formation was achieved by lo-' mol/L ATRA, which reduced the fibrin deposition by 80% ( P C .02) and platelet thrombus formation by 50% ( P C .05). In comparison, incubation of adherent monocytes with the anti-TF MoAb before the blood exposure, reduced the fibrin deposition by 8340 ( P < ,021 and platelet thrombus volume by 7596 ( P < .0008). Thus, ATRA is an effective downregulator of monocyte TF-PCA, and may reduce thrombotic complications at sites of plaque rupture, at plaque disruption after percutaneous transluminal angioplasty procedures, or on surfaces introduced by artificial arterial grafting. 0 1995 by The American Society of Hematology.
cribed to ATRA include increased tissue plasminogen activator activity in rats and expression of thrombomodulin by human U937 monoblast-like cells and human MEGOl megacaryocyte-like cells.'*.'' ATRA has also been reported to reduce the cancer procoagulant in acute promyelocytic leukemia cellsi4 and to improve the coagulopathy associated with acute promyelocytic leukemia. I5 We have investigated whether ATRA affects expression of monocyte T F and monocyte-mediated thrombus formation at arterial blood flow conditions. It was found that ATRA downregulated monocyte TF expression and reduced thrombus formation on adherent monocytes at arterial shear. Its inhibitory effect on TFlFVIIa dependent thrombus formation was significant, although not as potent as the reduction observed with a monoclonal anti-TF antibody efficiently blocking the TF/FVIIa coagulant activity.
MATERIALS AND METHODS

Blood Donors
The blood donors were healthy nonsmolung individuals, who denied intake of any drug at least 14 days before the blood sampling or blood perfusion experiments. Hematologic parameters (hemoglobin, hematocrit, leukocyte and platelet count) were within the normal ranges (Auto Counter AC 920, Swelab Instrument, Stockholm, Sweden).
Isolation of Human Blood Mononuclear Cells
Fresh peripheral blood mononuclear cells were isolated from blood drawn from healthy subjects by using Lymphoprep (Nycomed Pharma, Oslo, Norway) density preparation." Mononuclear cells were suspended in RPMI-l640 (Whittaker, Walkswille, ML) with 5% fetal calf serum (FCS) (GIBCO Life Technologies Ltd, Paisley, Scotland) and the number of cells adjusted to 2.0 X IO6/mL. Approximately 30% of the cells were monocytes (nonspecific esterase staining). The number of adherent monocytes on each cover slip was determined after 4 hours of incubation by counting cells on photographs taken from cover slips at original magnification X 63 with a light microscope (Axiophot 405M; Zeiss, Obercochen, Germany) in combination with a video camera (DXC-750D; Sony Corp, Tokyo, Japan) and a color video printer (UP-5OOOp; Sony). About 15% of the monocytes were removed from the cover slip after 5 minutes perfusion with blood at arterial shear.4
In parallel, adherent monocytes preincubated with or without ATRA were tested for procoagulant activity in a one-stage coagulation assay (Thrombotrack 4, Nycomed Pharma). The contribution of TF to the cell PCA was tested using an anti-TF MoAb (MoAb no. 4504) and, as control antibody, antihuman transfenin receptor CD 71 antibody (Dakopatts). The TF antigen expression was determined by Imubind Tissue Factor ELISA kit.
Adherent cells from the same donor as tested above, (1) with and without preincubation with ATRA, or (2) with or without the anti-TF MoAb (MoAb no. 4504), were subsequently used in blood perfusion experiments in the parallel-plate perfusion device (see below).
Testing for Endotoxin
The growth medium RPMI-1640 (Whitaker) and fetal calf serum (GIBCO) is tested for endotoxin contamination by the manufacturers, and has been routinely tested for endotoxin at The Department of Clinical Chemistry at Ullevil University Hospital, Oslo, Norway. The levels of endotoxin have been below the detection limit of 30 pg/mL." Thermanox cover slips, which are provided sterile from the manufacturer, were kept in 96% ethanol to avoid bacterial contamination. Each cover slip was handled under sterile conditions in a laminar air-flow hood. No detectable endotoxin (<30 pg/mL) was measured in growth medium incubated for 4 hours in Multi-Wells (6-wells) in the presence or absence of cover slips." However, we cannot exclude the possibility of the presence of trace amounts of endotoxin.
Blood Perjiision Experiments
Ex vivo perfusion experiments'* were performed in the parallelplate perfusion model of thrombogenesis as described in detail previo~sly."~ The Thermanox cover slip with adherent monocytes was positioned in the perfusion chamber and subsequently exposed to flowing nonanticoagulated human blood for 5 minutes. An antecubital vein was punctured with a 19-gauge Butterfly infusion set (Abbott Laboratories, North Chicago, IL), and the blood was drawn (10 mL/ minute) directly from the vein through the perfusion chamber by an occlusive roller pump (Minipuls 3; Gilson, Villiers Le Bel, France) placed distally to the perfusion chamber. The shear rate at the cell surface was 650 S-'. Each perfusion was terminated by a 20-second perfusion ( I O mL/min) with RPMI-1640 (Whittaker) medium at 37°C followed by a 40-second perfusion (10 mL/min) with freshly prepared fixation solution consisting of 2.5% glutaraldehyde/O. 1 m o m cacodylate in deionized water (pH 7.4) at 23°C. The specimens were stored in 7% sucrose/O.l m o m cacodylate buffer at 4"C, and finally embedded in Epon.''
Morphometry
Semithin Epon sections (1 pm) were prepared perpendicular to the direction of the blood flow at 1, 8, and 13 mm downstream from
ATRA Preparation
ATRA (Lot 63H0964; Sigma Chemical CO, St Louis, MO) was dissolved in absolute ethanol under nitrogen and diluted in RPMI-1640 (Whittaker)/5% FCS (GIBCO). All experiments were performed in subdued light, and the tubes and multiwell plates (NUNC AS, Roskilde, Denmark) were covered with aluminium foil. The final concentration of ethanol in the cell cultures was always less than 0.05% and this concentration had no effect on cell integrity as determined by the trypan blue exclusion test, or on cell PCA in a one-stage coagulation assay (Thrombotrack 4, Nycomed Pharma, Oslo, Norway) (see below).
Modulation of Monocyte PCA by LPS, Adhesion, and ATRA
Mononuclear cell suspended in RPMI 164015% FCS (2.0 X 10' mononuclear cellslml) were incubated in 50 mL tubes for 1 hour with ATRA in doses ranging from 10"" to m o m (37'C, 5% COz). Control mononuclear cell suspensions were incubated without the addition of ATRA. Mononuclear cells 4.0 X 10' were subsequently seeded on 4-cm2 Thermanox cover slips (Miles Laboratories, Naperville, IL) placed in Multi-Well (6 wells) plates (NUNC AS) and incubated for 4 hours with 0.5 pg/mL LPS from Escherichia coli OB 55 (Sigma). After the incubation, the cover slips were washed in RPMI-1640 (2 X 2 mL) to remove nonadherent cells. More than 90% of the adherent cells were monocytes, as determined by nonspecific esterase staining. Cell viability was determined by trypan blue exclusion test.
The adherent cells were tested for PCA in the one-stage coagulation assay after recovery from the cover slips with a rubber policeman (NUNC AS) and resuspension in 500 pL 10 mmom HEPES buffer (pH 7.2) supplemented with 0.15 m o m NaCl, 12.5 mmol/L CaCI2 (Sigma). After the addition of pooled normal human plasma (50 pL), the clotting time for four replicates (4 X 50 pL) was measured automatically at 37°C by a Thrombotrack 4 coagulometer. Six dilutions of a TF preparation from rabbit brain (Nycomed Pharma) were used to make a standard curve. The protein content of the resuspended cells (3 X 25 pL) was determined by a Micro BCA Protein Assay Reagent Kit according to the manufacturer's instructions (Pierce Chemical CO, Rockford, IL). Monocyte PCA was expressed in units of TF activity/100 pg protein because previous findings have shown that the monocyte PCA is virtually completely blocked by an anti-TF antibody (MoAb no. 4509, American Diagnostica, Greenwich, CT)! In the present investigation, the contribution of TF to monocyte PCA was probed with an anti-TF MoAb (MoAb no. 4504 [American Diagnostica], which efficiently blocks TF-FVIIa activity. An irrelevant MoAb of the same subclass IgG, (antihuman transfenin receptor CD71 antibody; Dakopatts, Glostrup, Denmark) served as control.
Modulation of Monocyte TF Antigen by LPS, Adhesion, and ATRA
Expression of TF antigen by nonstimulated Thermanox-adherent and LPS-stimulated (0.5 pg/mL) adherent monocytes, with and without inclusion of m o m ATRA as described above, was determined in cell lysates by an Imubind Tissue Factor Enzyme Linked Immunosorbent Assay (ELISA) kit (American Diagnostica) according to the manufacturer's directions.
Adherent Monocytes for Blood Perfusion Experiments
Mononuclear cells in suspension were incubated for 1 hour with mol& ATRA and subsequently seeded (4.0 X IO6 mononuclear cells) onto 4-cm2 cover slips (Miles Laboratories) as described above, but without the addition of LPS. Control cells were seeded the upstream edge of the cover slip.'o The sections were stained with toluidine blue and basic fuchsin. Thrombus formation was quantified as percent surface coverage with fibrin by light microscopy at original magnification X 1,000 (Standard 25; Zeiss, Obercochen, Germany)*' and as platelet thrombus volume (pm3/pm') derived from the sectional thrombus area (pm2/pm) assessed by computer-assisted morphometry (Kontron Vidas; Eching, Munich, Germany) at original magnification X 2,000 magnification as previously described."
Statistical Analysis
Statistical analysis was performed with paired or unpaired Student's t-test where appropriate. Perfusion data are expressed as mean 2 SEM and compared with the Wilcoxon signed-rank test. P < .05 was considered significant.
RESULTS
Monocyte-Themnox Adhesion and Cell Viability
Monocytes adhered randomly to the Thermanox cover slips. In the perfusion experiments with or without ATRA, 4 hours of incubation resulted in 529 5 15 adherent cells/ m m 2 (mean 2 SEM, n = 12) . In the perfusion experiments with or without the anti-TF MoAb, incubation resulted in 559 2 7 adherent cells/mm2 (mean 2 SEM, n = 8). Treatment with ATFU or the anti-TF MoAb did not affect the number of adherent cells when compared with adherence of untreated cells. Cell viability was greater than 99%.
Effect of ATRA on Monocyte TF PCA
Stimulation by LPS. Monocytes incubated with increasing concentrations of ATRA and then seeded on Thermanox cover slips and stimulated with LPS for 4 hours showed a dose-dependent reduction in the induction of PCA (Fig 1) . This LPS-induced PCA was inhibited by 95% by the anti-TF antibody ( P < .005, n = 6), whereas the control antibody had no significant effect on cell PCA.
Stimulation by adherence to Thermanox. Monocytes adherent for 4 hours to plastic cover slips expressed PCA, which was blocked by more than 80% by the anti-TF antibody ( P < ,002, n = lo), whereas the control antibody had no significant effect on cell PCA. In contrast, freshly isolated cells had undetectable activity. Thus, TF was identified as the main contributor to adherent cell PCA. When monocytes were incubated with m o m ATRA and then seeded on cover slips, the level of PCA induced by the adherence was downregulated by 40%, from 2.21 ? 0.73 to 1.32 ? 0.46 units TF activity/100 pg protein (P < .03, n = 7). Endotoxin levels tested in medium incubated for 4 hours with and without Thermanox cover slips did not exceed the detection limit of the test (30 pg/mL)," indicating that cell stimulation was caused by adhesion alone.
Effect of ATRA on Monocyte TF Antigen
TF antigen expression of Thermanox adherent and LPSstimulated adherent monocytes was determined by ELISA (Fig 2) .
Monocytes adherent for 4 hours to plastic cover slips expressed low levels of TF antigen. When cells were incubated with m o m ATRA before adherence, the TF antigen expression was reduced by 38% ( P < .0007). However, when cells were stimulated with LPS, expression of TF antigen after adherence to Thermanox was threefold increased ( P < .0001). When the cells were incubated with ATRA before LPS-stimulation and adherence, the induced TF antigen level was reduced by 30% ( P < ,0004).
Effect of ATRA or Anti-TF MoAb on Monocyte-Induced Thrombus Formation
Nonanticoagulated human blood was perfused over Thermanox-adherent monocytes for 5 minutes, at a wall shear rate of 650 S". Thrombus formation was assessed by morphometry as percent surface coverage with fibrin (fibrin deposition) and platelet thrombus volume (pm3/pm2) at three axial positions, 1, 8, and 13 mm downstream to the blood flow inlet at the cover slip.
Fibrin deposition. Monocytes adherent to cover slips for 4 hours triggered significant fibrin deposition. The deposition increased along the flow axis of the surface, at the downstream positions 8 and 13 mm ( P < .02) (Figs 3A and 4A ).
When monocytes were preincubated with m o m ATRA (before adhesion to cover slips), the fibrin deposition subsequently triggered was markedly reduced to the same level (<0.5%) at all axial positions (P < .03) (Fig 3A) . Preincubation of the cells with the anti-TF MoAb reduced the fibrin deposition to a similar extent as ATRA (<OS%) at the three axial positions (P < .02) (Fig 4A) .
Platelet thrombus volume.
Adherent procoagulant monocytes triggered pronounced platelet thrombus formation in flowing blood. However, thrombus formation was decreased downstream at the axial positions 8 and 13 mm (P < .07 and P <.03, respectively) (Fig 3B) . Preincubation of rnonocytes with ATRA reduced this thrombus formation at 1 and 13 mm, although not significantly (P < .07 and .07, respectively). However, the reduction was significant (50%, P < .01) when the average of all thrombus volumes in the treated group were compared with the corresponding volumes in the untreated group. The ATRA-dependent reduction nearly abolished the axially dependent differences in thrombus volume.
In comparison, the anti-TF MoAb reduced the sum of the platelet thrombus volume in the treated group when compared with the untreated group by 75% (P < .OOO1) (Fig 4B 
Morphology
Transverse sections of adherent monocytes perfused with nonanticoagulated blood showed fibrin strands sprouting out from the cells and partly onto the surface of the Thermanox cover slip. The platelet thrombi appeared to form on fibrin strands in close proximity to adherent monocytes or directly on the surface of the monocytes. However, cells preincubated with ATRA produced very little deposition of fibrin and smaller platelet thrombi (Fig 5) .
DISCUSSION
TF in vessel walls is apparently a key activator of coagulation in hemostasis and thrombosis.2"'2 In diseased arteries, monocyte-derived macrophages of atherosclerotic plaques' express TF2*? which may become exposed to the blood stream after plaque rupture or disruption, resulting in thrombotic complications. On the other hand, circulating monocytes can be stimulated to express TF after adhesion to artifici?l surfaces:.' a process that may play a role in artificial arterial graft failure.' Therefore, agents that are able to downregulate induction of TF in macrophageshonocytes may attenuate the thrombotic risk associated with both mechanical restoration of vessel patency and arterial grafting.
Because ATRA downregulates induction of TF expression in vascular endothelial cells"' and has been reported to reduce monocyte PCA," it was of interest to investigate the effect of ATRA on induction of TF expression in blood monocytes. It was also of interest to investigate whether ATRA modulates monocyte TF PCA, which was recently found to mediate arterial thrombus formation in a parallel-plate perfusion chamber device? The experimental conditions chosen (wall shear rate of 650 S-') mimicked to some extent a successful post-PTCA situation, where the luminal dimension of the coronary artery has been restored, but the plaques abundant macrophage associated TF is exposed to the blood stream. The experimental conditions are also very relevant to the situation in a small calibre artificial graft with adherent blood monocytes.
ATRA significantly downregulated induction of monocyte TF PCA and TF antigen-expression, independent of whether induction was triggered by adhesion to Thermanox or by stimulation with LPS and adhesion. However, it should be emphasized that incubation with ATRA was performed in a mononuclear leukocyte suspension where only 30% of the cells were monocytes. Therefore, we cannot exclude the possibility that the TF inhibitory effect could be caused by ATRA's effect on, eg, lymphocytes that secondarily affected the monocyte TF expression. Nevertheless, ATRA reduced the level of TF expression induced either by adhesion or by adhesion and LPS. The reduction of TF expression by ATRA may have significance because monocytes are apparently implicated in several pathophysiologic conditions associated with hypercoagulability. Moreover, the effect of ATRA on TF expression by human monocytes in vitro is similar to its effect on cultured human endothelium."
ATRA dependent downregulation of TF expression by Thermanox adherent monocytes resulted in significant reduction of fibrin deposition and platelet thrombus formation at arterial shear conditions. The beneficial effect of ATRA was further evidenced by the significant correlation between the reduction in monocyte PCA and fibrin deposition in arterial flow. It was also noted that the size of the monocyte triggered platelet thrombi were in the range of that observed on human type 111 collagen fibrils.*.33 Thus, the relatively low surface density of adherent monocytes used in these perfusion experiments was able to trigger platelet thrombus formation as efficiently as fibrillar collagen spray-coated on the entire cover slip surface. This impressive level of thrombogenicity suggests that procoagulant monocyteshacrophages contribute significantly to arterial thrombus formation at sites of atherosclerotic lesions. Other investigators and our laboratory have previously used endothelial or subendothelial matrix TF as a source of TF in human studies of thr~mbogenesis~"~" and animal models of thrombogenesis.31.32 These studies conclude that TF is the principle mediator of thrombogenesis because thrombus formation is efficiently inhibited by anti-TF MoAbs. In the present investigation, pretreatment of monocytes with ATRA at a concentration of mol/L reduced significantly TF expression, TF PCA, and the platelet-thrombus formation at arterial shear. Fibrin deposition was virtually abolished by ATRA. Similar reductions in monocyte TF expression and in TFdependent thrombus formation was observed with the anti-TF MoAb. Thus, the beneficial effect of ATRA on the monocyte-induced thrombus formation was apparently mediated through downregulation of TF expression.
It was observed that the platelet thrombus formation was reduced downstream. A similar reduction along the surface was previously reported for other TF containing surfaces such as artery s~bendothelium~~ and extracellular matrix of LPS-stimulated endothelium."' This effect has been ascribed to consumption of platelets from the blood layers streaming adjacent to the surface by rapidly growing t h r~m b i . '~.~~ Thus, fewer platelets are available to participate in downstream thrombus formation. In contrast, fibrin deposition increased downstream, also in accordance with findings with TF presented by artery s~bendothelium~~ and LPS-stimulated endothelial extracellular matrix.35 It has been suggested that this increase is caused by translocation of activated coagulation factors such as FIXa, FXa, and thrombin from upstream locations to binding sites on downstream deposited blood cells. Nevertheless, ATRA efficiently reduced thrombus formation on the procoagulant monocytes, which resulted in no axial differences in either platelet thrombus formation or fibrin deposition. Thus, ATRA persistently reduced thrombus formation along the entire length of the cover slip of adherent procoagulant cells. Previous evaluation of the antithrombotic effect of the platelet inhibitors aspirin and clopidogrel along the axis of a collagen-rich surface36 established inhibition of thrombus formation by aspirin only upstream, whereas clopidogrel interrupted thrombus formation persistently along the entire 13-mm thrombogenic axis, much like ATRA. Apparently, detailed analysis of antithrombotics should also include information of thrombus formation from well-defined axial positions. However, it should be emphasized that large areas of artificial surfaces are implanted in the human vasculature, and mechanical trauma inflicted to arteries by FTCA procedures may result in exposure of larger procoagulant surfaces than those used in our study.
Plasma proteins adsorbed to artificial vascular graft materials may result in platelet adhesion and aggregate formamonocytes and neutrophils also attach to the surface within 24 hours after graft im~lantation~~ caused by the acute inflammatory response.@"' Our observation that adhesion of nonstimulated monocytes to artificial surfaces is associated with spontaneous induction of TF expression is consistent with our previous findings4 and those of
The thrombus formation elicited by adherent procoagulant monocytes in the present investigation suggests a prominent role for TF in the failure of artificial vascular grafts.
We conclude that downregulation of TF expression and associated PCA of monocytes and macrophages by treatment with retinoids may be a valuable means of reducing thrombotic complications post-FTCA or in arterial grafting with artificial vascular grafts. There may also be benefits in other pathophysiologic conditions associated with hypercoagulability and implications in dietary contributors to the incidence of arteriosclerosis. tion,'7,38 and eventually in acute graft failure. However,
